AstraZeneca snaps up Amolyt Pharma for over $1 billion
There has been talk that perhaps dealmaking in the biopharmaceutical industry was waning following the the string of deal announcements in December 2023.
However, AstraZeneca has just put paid to that theory by announcing another takeover deal. This time the FTSE 100-listed company has agreed to purchase Amolyt Pharma, a France-based company focused on developing novel treatments for rare endocrine diseases...
Register
Register for free to see rest of this article and all public articles from Betaville
Login / RegisterDate: Thursday, 14 March 2024, 7:19 am